Because of your support, the International Myeloma Foundation (IMF) made huge strides in myeloma research, education, support, and advocacy in 2023. Read the full 2023 Innovation and Impact Report now.

The IMF's Immune Therapy Registry, an International Myeloma Working Group (IMWG) project, is the first global clinical database study that will collect data from patients with relapsed and/or high-risk myeloma who are receiving immune therapies. Read more on p. 4 of the report.

A combined project of the IMF's Asian Myeloma Network (AMN) and International Myeloma Working Group (IMWG), the Virtual Tissue Bank will collect data from sites around the world and share the data through a web-based portal. Read more on p. 5 of the report.

To better serve our patient community, the IMF has deployed Data Lakes for Nonprofits — powered by Amazon Web Services (AWS) and offered by AWS and Salesforce. The IMF will be creating a more patient-focused digital ecosystem known as the Myeloma Knowledge Platform. Read more on pp. 8-9 of the report. 

The IMF's iStopMM project proudly showcased four oral and two poster abstracts at the 65th American Society of Hematology Annual Meeting and Exposition in San Diego, CA, in December 2023. Read more on pp. 16-17 of the report. 

GMAN unites 30+ global advocacy leaders from 30 countries.

In 2023, the IMF's Asian Myeloma Network held its annual summit in Bangkok, Thailand; conducted 7 meetings in the Asia-Pacific region; and coordinated 7 clinical trials. 

The Medical Student Scholars for Health Equity program resulted in 11 poster abstracts, 2 ASH posters, and 1 ASH Award.

At the annual IMF Support Group Leaders Summit, 90 suuport group leaders from 74 support groups attend, including 63 returning leaders and 27 first-time attendees.